Acquired Immunodeficiency Syndrome (AIDS) Market Poised for 5.3 % Growth, Set to Hit $41.57 Billion by 2029

Which drivers are expected to have the greatest impact on the over the acquired immunodeficiency syndrome (aids) market's growth?
The increasing prevalence of HIV infections is expected to contribute to the expansion of the acquired immunodeficiency syndrome (AIDS) market. HIV infections occur due to the human immunodeficiency virus (HIV), which weakens the immune system, reducing the body's ability to fight infections and diseases. The rise in HIV cases is linked to factors such as unprotected sexual contact with infected individuals, sharing needles, receiving contaminated blood products, having multiple sexual partners, and pre-existing sexually transmitted infections. Managing acquired immunodeficiency syndrome (AIDS) involves early diagnosis, broader access to effective antiretroviral therapies, improved prevention strategies, and strengthened healthcare systems, all of which help control the virus's spread. For example, in November 2024, the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, reported 112,883 HIV diagnoses in 2023 across 47 out of 53 countries in the region, with 24,731 cases recorded in the European Union/European Economic Area (EU/EEA). The overall HIV diagnosis rate rose to 12.7 per 100,000 people, marking a 2.4% increase from the 12.4 per 100,000 reported in 2022. Therefore, the growing number of HIV infections is driving the acquired immunodeficiency syndrome (AIDS) market.

Get Your Acquired Immunodeficiency Syndrome (AIDS) Market Report Here:
https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

What is the future CAGR of the acquired immunodeficiency syndrome (aids) market, and how will it impact industry expansion?
The acquired immunodeficiency syndrome (AIDS) market has also grown substantially in recent years. It is expected to increase from $32.09 billion in 2024 to $33.85 billion in 2025, with a CAGR of 5.5%. This growth in the past can be attributed to rising HIV infection rates, increased government funding for HIV treatment, the expansion of global awareness programs, advancements in diagnostic capabilities, and greater support from non-governmental organizations.

The acquired immunodeficiency syndrome (AIDS) market size is forecasted to grow significantly over the next few years. By 2029, it is set to reach $41.57 billion, with a compound annual growth rate (CAGR) of 5.3%. The projected growth is attributed to the increasing demand for long-acting injectable therapies, the growing adoption of pre-exposure prophylaxis (PrEP), rising investments in HIV cure research, the expansion of telemedicine services for HIV care, a heightened focus on personalized medicine, and greater awareness regarding early HIV diagnosis. Notable trends expected during this period include a shift toward single-tablet regimens, increasing preference for injectable and implantable HIV treatments, a growing demand for digital health solutions in HIV management, a rising interest in functional HIV cure strategies, and an expanding role of artificial intelligence in drug discovery.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp

What are the most significant trends transforming the acquired immunodeficiency syndrome (aids) market today?
In the acquired immunodeficiency syndrome (AIDS) market, companies are emphasizing long-acting injectables to improve patient compliance, reduce dosing frequency, and offer a more convenient alternative to daily oral antiretroviral treatments. For instance, in January 2025, GSK plc., a UK-based pharmaceutical company, announced European Commission approval for its long-acting injectable regimen of Vocabria (cabotegravir) plus Rekambys (rilpivirine) for adolescents living with HIV. Administered once every one or two months, this treatment improves adherence rates, especially among those who struggle with daily pill regimens.

Which key market segments comprise the acquired immunodeficiency syndrome (aids) market and drive its revenue growth?
The acquired immunodeficiency syndrome (AIDS) market covered in this report is segmented -

1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral, Parenteral
4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications
5) By Distribution Channel: Offline, Online

Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21076

What regions are at the forefront of acquired immunodeficiency syndrome (aids) market expansion?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (AIDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the leading players fueling growth in the acquired immunodeficiency syndrome (aids) market?
Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy's Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp

What Is Covered In The Acquired Immunodeficiency Syndrome (AIDS) Global Market Report?

•Market Size Forecast: Examine the acquired immunodeficiency syndrome (aids) market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the acquired immunodeficiency syndrome (aids) market for a structured understanding.
•Key Players Overview: Analyze major players in the acquired immunodeficiency syndrome (aids) market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the acquired immunodeficiency syndrome (aids) market.
•Segment Contributions: Evaluate how different segments drive overall growth in the acquired immunodeficiency syndrome (aids) market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the acquired immunodeficiency syndrome (aids) market.
•Industry Challenges: Identify potential risks and obstacles affecting the acquired immunodeficiency syndrome (aids) market.
•Competitive Landscape: Review strategic developments in the acquired immunodeficiency syndrome (aids) market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.